On the contrary, higher IGF-1 xULN values at diagnosis [OR 2.304 (95%CI 1.254-4.234)] and a T2-weighted hypointense signal of the pituitary tumor [OR 18 (95%CI 1.754-184.679] were associated with a significantly higher likelihood of achieving a >50% IGF-1 reduction after SRL therapy (Table 2). Here, IGF1 is linked to pituitary tumor.